25 XP   0   0   10

Cartesian Therapeutics Inc.
Buy, Hold or Sell?

Let's analyze Cartesian Therapeutics Inc. together

I guess you are interested in Cartesian Therapeutics Inc.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cartesian Therapeutics Inc.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Cartesian Therapeutics Inc.

I send you an email if I find something interesting about Cartesian Therapeutics Inc..

Quick analysis of Cartesian Therapeutics Inc. (30 sec.)










What can you expect buying and holding a share of Cartesian Therapeutics Inc.? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
13.2%

What is your share worth?

Current worth
$-6.56
Expected worth in 1 year
$-17.32
How sure are you?
36.8%

+ What do you gain per year?

Total Gains per Share
$-10.75
Return On Investment
-61.0%

For what price can you sell your share?

Current Price per Share
$17.62
Expected price per share
$11.67 - $41.87
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Cartesian Therapeutics Inc. (5 min.)




Live pricePrice per Share (EOD)

$17.62

Intrinsic Value Per Share

$-51.83 - $-61.65

Total Value Per Share

$-58.40 - $-68.22

2. Growth of Cartesian Therapeutics Inc. (5 min.)




Is Cartesian Therapeutics Inc. growing?

Current yearPrevious yearGrowGrow %
How rich?-$116.8m$85.7m-$193.5m-179.5%

How much money is Cartesian Therapeutics Inc. making?

Current yearPrevious yearGrowGrow %
Making money-$63.7m-$3.7m-$59.9m-94.1%
Net Profit Margin-869.2%-86.5%--

How much money comes from the company's main activities?

3. Financial Health of Cartesian Therapeutics Inc. (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Cartesian Therapeutics Inc.? (5 min.)

Welcome investor! Cartesian Therapeutics Inc.'s management wants to use your money to grow the business. In return you get a share of Cartesian Therapeutics Inc..

What can you expect buying and holding a share of Cartesian Therapeutics Inc.?

First you should know what it really means to hold a share of Cartesian Therapeutics Inc.. And how you can make/lose money.

Speculation

The Price per Share of Cartesian Therapeutics Inc. is $17.62. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cartesian Therapeutics Inc..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cartesian Therapeutics Inc., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-6.56. Based on the TTM, the Book Value Change Per Share is $-2.69 per quarter. Based on the YOY, the Book Value Change Per Share is $0.94 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cartesian Therapeutics Inc..

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-3.19-18.1%-3.58-20.3%-0.21-1.2%-0.84-4.8%-0.79-4.5%
Usd Book Value Change Per Share18.17103.1%-2.69-15.3%0.945.3%-0.35-2.0%-0.17-1.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.080.5%0.060.4%
Usd Total Gains Per Share18.17103.1%-2.69-15.3%0.945.3%-0.27-1.5%-0.11-0.6%
Usd Price Per Share0.65-1.42-2.74-4.24-10.21-
Price to Earnings Ratio-0.05--0.50-0.16-0.21--1.92-
Price-to-Total Gains Ratio0.04--2.93--2.48--48.25--54.74-
Price to Book Ratio-0.10-0.28-0.57-118.27-66.59-
Price-to-Total Gains Ratio0.04--2.93--2.48--48.25--54.74-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share17.62
Number of shares56
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.08
Usd Book Value Change Per Share-2.69-0.35
Usd Total Gains Per Share-2.69-0.27
Gains per Quarter (56 shares)-150.56-14.97
Gains per Year (56 shares)-602.22-59.87
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-602-61218-78-70
20-1204-121436-156-130
30-1807-181654-233-190
40-2409-241872-311-250
50-3011-302090-389-310
60-3613-3622108-467-370
70-4216-4224126-545-430
80-4818-4826144-623-490
90-5420-5428162-700-550
100-6022-6030180-778-610

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%5.07.00.041.7%5.015.00.025.0%6.032.00.015.8%6.032.00.015.8%
Book Value Change Per Share1.03.00.025.0%6.06.00.050.0%8.012.00.040.0%13.022.03.034.2%13.022.03.034.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%3.00.017.015.0%5.00.033.013.2%5.00.033.013.2%
Total Gains per Share1.03.00.025.0%6.06.00.050.0%9.011.00.045.0%14.021.03.036.8%14.021.03.036.8%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Cartesian Therapeutics Inc.

About Cartesian Therapeutics Inc.

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Fundamental data was last updated by Penke on 2024-06-23 06:40:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Cartesian Therapeutics Inc..

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cartesian Therapeutics Inc. earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cartesian Therapeutics Inc. to the Biotechnology industry mean.
  • A Net Profit Margin of -973.0% means that $-9.73 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cartesian Therapeutics Inc.:

  • The MRQ is -973.0%. The company is making a huge loss. -2
  • The TTM is -869.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-973.0%TTM-869.2%-103.9%
TTM-869.2%YOY-86.5%-782.7%
TTM-869.2%5Y-6,544.1%+5,674.9%
5Y-6,544.1%10Y-15,595.0%+9,051.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-973.0%-168.0%-805.0%
TTM-869.2%-209.9%-659.3%
YOY-86.5%-242.3%+155.8%
5Y-6,544.1%-401.7%-6,142.4%
10Y-15,595.0%-532.2%-15,062.8%
1.1.2. Return on Assets

Shows how efficient Cartesian Therapeutics Inc. is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cartesian Therapeutics Inc. to the Biotechnology industry mean.
  • -17.5% Return on Assets means that Cartesian Therapeutics Inc. generated $-0.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cartesian Therapeutics Inc.:

  • The MRQ is -17.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -23.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.5%TTM-23.1%+5.6%
TTM-23.1%YOY-2.6%-20.5%
TTM-23.1%5Y-11.7%-11.4%
5Y-11.7%10Y-16.7%+5.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.5%-11.9%-5.6%
TTM-23.1%-11.9%-11.2%
YOY-2.6%-11.3%+8.7%
5Y-11.7%-13.5%+1.8%
10Y-16.7%-14.9%-1.8%
1.1.3. Return on Equity

Shows how efficient Cartesian Therapeutics Inc. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cartesian Therapeutics Inc. to the Biotechnology industry mean.
  • 0.0% Return on Equity means Cartesian Therapeutics Inc. generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cartesian Therapeutics Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-8.1%+8.1%
TTM-8.1%YOY-5.6%-2.5%
TTM-8.1%5Y-1,468.4%+1,460.4%
5Y-1,468.4%10Y-801.1%-667.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.2%+14.2%
TTM-8.1%-15.7%+7.6%
YOY-5.6%-14.3%+8.7%
5Y-1,468.4%-19.2%-1,449.2%
10Y-801.1%-19.7%-781.4%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Cartesian Therapeutics Inc..

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cartesian Therapeutics Inc. is operating .

  • Measures how much profit Cartesian Therapeutics Inc. makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cartesian Therapeutics Inc. to the Biotechnology industry mean.
  • An Operating Margin of -223.4% means the company generated $-2.23  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cartesian Therapeutics Inc.:

  • The MRQ is -223.4%. The company is operating very inefficient. -2
  • The TTM is -302.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-223.4%TTM-302.4%+79.0%
TTM-302.4%YOY-82.1%-220.4%
TTM-302.4%5Y-6,364.4%+6,061.9%
5Y-6,364.4%10Y-15,362.9%+8,998.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-223.4%-354.6%+131.2%
TTM-302.4%-225.9%-76.5%
YOY-82.1%-252.2%+170.1%
5Y-6,364.4%-428.3%-5,936.1%
10Y-15,362.9%-531.1%-14,831.8%
1.2.2. Operating Ratio

Measures how efficient Cartesian Therapeutics Inc. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.23 means that the operating costs are $3.23 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cartesian Therapeutics Inc.:

  • The MRQ is 3.234. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.089. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.234TTM4.089-0.855
TTM4.089YOY1.857+2.232
TTM4.0895Y97.270-93.181
5Y97.27010Y250.563-153.293
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2343.004+0.230
TTM4.0893.332+0.757
YOY1.8573.502-1.645
5Y97.2705.271+91.999
10Y250.5636.915+243.648
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Cartesian Therapeutics Inc..

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cartesian Therapeutics Inc. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.03 means the company has $3.03 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cartesian Therapeutics Inc.:

  • The MRQ is 3.031. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.262. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.031TTM3.262-0.231
TTM3.262YOY5.741-2.479
TTM3.2625Y3.067+0.195
5Y3.06710Y3.867-0.800
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0313.767-0.736
TTM3.2624.000-0.738
YOY5.7414.905+0.836
5Y3.0675.883-2.816
10Y3.8676.286-2.419
1.3.2. Quick Ratio

Measures if Cartesian Therapeutics Inc. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cartesian Therapeutics Inc. to the Biotechnology industry mean.
  • A Quick Ratio of 2.94 means the company can pay off $2.94 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cartesian Therapeutics Inc.:

  • The MRQ is 2.941. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.141. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.941TTM3.141-0.200
TTM3.141YOY6.225-3.083
TTM3.1415Y3.173-0.032
5Y3.17310Y4.302-1.129
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9413.054-0.113
TTM3.1413.506-0.365
YOY6.2254.756+1.469
5Y3.1735.757-2.584
10Y4.3026.338-2.036
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Cartesian Therapeutics Inc..

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cartesian Therapeutics Inc. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cartesian Therapeutics Inc. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.36 means that Cartesian Therapeutics Inc. assets are financed with 135.9% credit (debt) and the remaining percentage (100% - 135.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cartesian Therapeutics Inc.:

  • The MRQ is 1.359. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.191. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.359TTM1.191+0.168
TTM1.191YOY0.501+0.690
TTM1.1915Y0.947+0.244
5Y0.94710Y0.858+0.090
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3590.330+1.029
TTM1.1910.342+0.849
YOY0.5010.287+0.214
5Y0.9470.368+0.579
10Y0.8580.382+0.476
1.4.2. Debt to Equity Ratio

Measures if Cartesian Therapeutics Inc. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cartesian Therapeutics Inc. to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cartesian Therapeutics Inc.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.472-0.472
TTM0.472YOY1.013-0.541
TTM0.4725Y43.093-42.620
5Y43.09310Y23.397+19.696
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.365-0.365
TTM0.4720.415+0.057
YOY1.0130.370+0.643
5Y43.0930.443+42.650
10Y23.3970.476+22.921
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Cartesian Therapeutics Inc.

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cartesian Therapeutics Inc. generates.

  • Above 15 is considered overpriced but always compare Cartesian Therapeutics Inc. to the Biotechnology industry mean.
  • A PE ratio of -0.05 means the investor is paying $-0.05 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cartesian Therapeutics Inc.:

  • The EOD is -1.380. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.051. Based on the earnings, the company is expensive. -2
  • The TTM is -0.498. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.380MRQ-0.051-1.329
MRQ-0.051TTM-0.498+0.447
TTM-0.498YOY0.160-0.658
TTM-0.4985Y0.213-0.711
5Y0.21310Y-1.924+2.137
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.380-2.341+0.961
MRQ-0.051-2.997+2.946
TTM-0.498-2.882+2.384
YOY0.160-3.553+3.713
5Y0.213-6.262+6.475
10Y-1.924-6.288+4.364
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cartesian Therapeutics Inc.:

  • The EOD is -4.746. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.175. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.584. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.746MRQ-0.175-4.570
MRQ-0.175TTM-0.584+0.409
TTM-0.584YOY0.140-0.724
TTM-0.5845Y-7.510+6.926
5Y-7.51010Y-4.463-3.047
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.746-2.932-1.814
MRQ-0.175-3.739+3.564
TTM-0.584-3.776+3.192
YOY0.140-4.917+5.057
5Y-7.510-7.942+0.432
10Y-4.463-8.503+4.040
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cartesian Therapeutics Inc. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -0.10 means the investor is paying $-0.10 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cartesian Therapeutics Inc.:

  • The EOD is -2.685. Based on the equity, the company is expensive. -2
  • The MRQ is -0.099. Based on the equity, the company is expensive. -2
  • The TTM is 0.277. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-2.685MRQ-0.099-2.586
MRQ-0.099TTM0.277-0.376
TTM0.277YOY0.575-0.298
TTM0.2775Y118.274-117.997
5Y118.27410Y66.594+51.680
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.6851.843-4.528
MRQ-0.0992.249-2.348
TTM0.2772.301-2.024
YOY0.5752.412-1.837
5Y118.2743.782+114.492
10Y66.5944.212+62.382
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cartesian Therapeutics Inc..

3.1. Institutions holding Cartesian Therapeutics Inc.

Institutions are holding 11.836% of the shares of Cartesian Therapeutics Inc..

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Artal Group S A1.71130.2094913663500
2023-12-31FMR Inc1.44760.000477284375160041200.9052
2023-12-31BlackRock Inc1.40820.00017517950-227237-2.9339
2023-12-31Vanguard Group Inc1.35680.00017244032527050.7329
2023-12-31Goldman Sachs Group Inc0.5570.000229740001635731122.2274
2023-12-31Geode Capital Management, LLC0.45670.00022438160533862.2386
2023-12-31State Street Corporation0.41240.000122018521685888.2915
2023-12-31JPMorgan Chase & Co0.27740.00011480810-20219-1.347
2023-12-31Northern Trust Corp0.17710.0001945685-1649-0.1741
2023-12-31CM Management, LLC0.13110.387870000000
2023-12-31Delphi Financial Group Inc0.12380.267166085200
2023-12-31Renaissance Technologies Corp0.0970.0006517800-208200-28.6777
2023-12-31Nuveen Asset Management, LLC0.09180.000149032000
2023-12-31Bridgeway Capital Management, LLC0.08540.006745580000
2023-12-31Bank of New York Mellon Corp0.06260.0001334260-256724-43.4401
2023-12-31Charles Schwab Investment Management Inc0.06090.000132530800
2023-12-31Millennium Management LLC0.04040.00012157752157750
2023-12-31Barclays PLC0.03750.0001200171140506235.4915
2023-12-31Bank of America Corp0.03590191870104683120.0672
2023-12-31Ironwood Investment Management LLC0.0320.0618170626-8505-4.7479
Total 8.60290.935245930343+6808881+14.8%

3.2. Funds holding Cartesian Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31Fidelity Small Cap Index0.21190.00281131378-45264-3.8469
2024-04-30Fidelity Select Biotechnology2.85770.2594508559340477.1752
2024-03-31Nuveen Equity Index R60.06190.000533057900
2024-03-31NT R2000 Index Fund - NL0.06140.0028327583-18557-5.3611
2023-09-30BlackRock Extended Mkt Composite0.05810.002331020220320.6594
2024-03-31Bridgeway Ultra-Small Company Market0.05340.0961285000-150000-34.4828
2024-03-31BlackRock Extended Equity Market K0.05010.0012267730960.0359
2023-12-31NT R2000 Value Index Fund - NL0.0490.004826151400
2024-03-31NT R2000 Index Fund - DC - NL - 20.04870.0028260146-12443-4.5647
2024-03-31Russell 2000 Index Non-Lendable Fund E0.04190.002822384914430.6488
2023-12-31NT R2000 Value Index Fund - L0.03070.004316409800
2024-03-31BlackRock Russell 2500™ Index F0.03030.0011161900670.0414
2024-03-31Nuveen Small Cap Blend Idx R60.02990.002915974100
2024-04-30Vanguard Total Stock Mkt Idx Inv0.71160.0002126634110.0087
2024-03-31BlackRock Russell 2000® Index NL F0.02330.0028124415-5004-3.8665
2023-12-31ERSTE STOCK BIOTEC EUR R01 A0.020.0288107000-7-0.0065
2024-04-30JPMorgan US Small Company L0.58740.2461045341045340
2024-03-31LVIP SSgA Small Cap Index Std0.01870.00299980000
2024-03-31NT Ext Equity Mkt Idx Fd - L0.01850.0019871900
2024-03-31NT Ext Equity Mkt Idx Fd - NL0.01760.00099397400
Total 4.98210.66645147355-89045-1.7%

3.3. Insider Transactions

Insiders are holding 60.727% of the shares of Cartesian Therapeutics Inc..

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-18Timothy A SpringerBUY63418
2024-03-14Timothy A SpringerBUY2161216.2
2024-03-11Timothy A SpringerBUY4019.5
2024-03-08Timothy A SpringerBUY16019.8
2024-02-06Timothy A SpringerBUY2619.5
2024-01-17Timothy A SpringerBUY2620.7
3rd party ad coffee SUPPORTERis ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cartesian Therapeutics Inc. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--18.172-2.688+115%0.938+1836%-0.347+102%-0.173+101%
Book Value Per Share---6.563-6.058-8%4.817-236%-0.256-96%0.427-1637%
Current Ratio--3.0313.262-7%5.741-47%3.067-1%3.867-22%
Debt To Asset Ratio--1.3591.191+14%0.501+171%0.947+43%0.858+58%
Debt To Equity Ratio---0.472-100%1.013-100%43.093-100%23.397-100%
Dividend Per Share----0%-0%0.080-100%0.064-100%
Eps---3.193-3.580+12%-0.212-93%-0.839-74%-0.792-75%
Free Cash Flow Per Share---0.928-0.829-11%-0.413-55%-0.296-68%-0.392-58%
Free Cash Flow To Equity Per Share--1.490-0.411+128%0.118+1160%-0.005+100%0.074+1916%
Gross Profit Margin--1.0051.001+0%1.000+0%1.000+0%1.000+0%
Intrinsic Value_10Y_max---61.653--------
Intrinsic Value_10Y_min---51.833--------
Intrinsic Value_1Y_max---2.457--------
Intrinsic Value_1Y_min---2.411--------
Intrinsic Value_3Y_max---10.218--------
Intrinsic Value_3Y_min---9.698--------
Intrinsic Value_5Y_max---21.398--------
Intrinsic Value_5Y_min---19.617--------
Market Cap313567282.000+96%11567465.00025356773.085-54%48672333.500-76%357333992.036-97%351389905.729-97%
Net Profit Margin---9.730-8.692-11%-0.865-91%-65.441+573%-155.950+1503%
Operating Margin---2.234-3.024+35%-0.821-63%-63.644+2749%-153.629+6776%
Operating Ratio--3.2344.089-21%1.857+74%97.270-97%250.563-99%
Pb Ratio-2.685-2611%-0.0990.277-136%0.575-117%118.274-100%66.594-100%
Pe Ratio-1.380-2611%-0.051-0.498+878%0.160-132%0.213-124%-1.924+3680%
Price Per Share17.620+96%0.6501.425-54%2.735-76%4.235-85%10.211-94%
Price To Free Cash Flow Ratio-4.746-2611%-0.175-0.584+234%0.140-225%-7.510+4190%-4.463+2449%
Price To Total Gains Ratio0.970+96%0.036-2.931+8294%-2.479+7029%-48.254+135000%-54.736+153121%
Quick Ratio--2.9413.141-6%6.225-53%3.173-7%4.302-32%
Return On Assets---0.175-0.231+32%-0.026-85%-0.117-33%-0.167-5%
Return On Equity----0.0810%-0.0560%-14.6840%-8.0110%
Total Gains Per Share--18.172-2.688+115%0.938+1836%-0.267+101%-0.109+101%
Usd Book Value---116800000.000-107801750.000-8%85730000.000-236%-4809550.000-96%8877710.526-1416%
Usd Book Value Change Per Share--18.172-2.688+115%0.938+1836%-0.347+102%-0.173+101%
Usd Book Value Per Share---6.563-6.058-8%4.817-236%-0.256-96%0.427-1637%
Usd Dividend Per Share----0%-0%0.080-100%0.064-100%
Usd Eps---3.193-3.580+12%-0.212-93%-0.839-74%-0.792-75%
Usd Free Cash Flow---16519000.000-14747750.000-11%-7352000.000-55%-7968050.000-52%-9190105.263-44%
Usd Free Cash Flow Per Share---0.928-0.829-11%-0.413-55%-0.296-68%-0.392-58%
Usd Free Cash Flow To Equity Per Share--1.490-0.411+128%0.118+1160%-0.005+100%0.074+1916%
Usd Market Cap313567282.000+96%11567465.00025356773.085-54%48672333.500-76%357333992.036-97%351389905.729-97%
Usd Price Per Share17.620+96%0.6501.425-54%2.735-76%4.235-85%10.211-94%
Usd Profit---56824000.000-63717750.000+12%-3765500.000-93%-18049450.000-68%-15210105.263-73%
Usd Revenue--5840000.0006476500.000-10%20679000.000-72%12880800.000-55%7260184.211-20%
Usd Total Gains Per Share--18.172-2.688+115%0.938+1836%-0.267+101%-0.109+101%
 EOD+7 -1MRQTTM+17 -16YOY+13 -205Y+15 -2010Y+14 -21

4.2. Fundamental Score

Let's check the fundamental score of Cartesian Therapeutics Inc. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.380
Price to Book Ratio (EOD)Between0-1-2.685
Net Profit Margin (MRQ)Greater than0-9.730
Operating Margin (MRQ)Greater than0-2.234
Quick Ratio (MRQ)Greater than12.941
Current Ratio (MRQ)Greater than13.031
Debt to Asset Ratio (MRQ)Less than11.359
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.175
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Cartesian Therapeutics Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5035.703
Ma 20Greater thanMa 5026.650
Ma 50Greater thanMa 10025.899
Ma 100Greater thanMa 20022.597
OpenGreater thanClose16.160
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets325,207
Total Liabilities442,007
Total Stockholder Equity-116,800
 As reported
Total Liabilities 442,007
Total Stockholder Equity+ -116,800
Total Assets = 325,207

Assets

Total Assets325,207
Total Current Assets111,109
Long-term Assets214,098
Total Current Assets
Cash And Cash Equivalents 103,418
Net Receivables 4,376
Other Current Assets 3,315
Total Current Assets  (as reported)111,109
Total Current Assets  (calculated)111,109
+/-0
Long-term Assets
Property Plant Equipment 11,958
Goodwill 48,163
Long Term Investments 2,000
Intangible Assets 150,600
Long-term Assets Other 1,377
Long-term Assets  (as reported)214,098
Long-term Assets  (calculated)214,098
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities36,654
Long-term Liabilities405,353
Total Stockholder Equity-116,800
Total Current Liabilities
Short-term Debt 2,229
Accounts payable 2,517
Other Current Liabilities 31,496
Total Current Liabilities  (as reported)36,654
Total Current Liabilities  (calculated)36,242
+/- 412
Long-term Liabilities
Capital Lease Obligations 10,457
Long-term Liabilities Other 376,517
Long-term Liabilities  (as reported)405,353
Long-term Liabilities  (calculated)386,974
+/- 18,379
Total Stockholder Equity
Common Stock1
Retained Earnings -671,471
Accumulated Other Comprehensive Income -4,605
Other Stockholders Equity 559,275
Total Stockholder Equity (as reported)-116,800
Total Stockholder Equity (calculated)-116,800
+/-0
Other
Capital Stock1
Cash and Short Term Investments 103,418
Common Stock Shares Outstanding 5,414
Current Deferred Revenue412
Liabilities and Stockholders Equity 325,207
Net Debt -92,961
Net Invested Capital -116,800
Net Working Capital 74,455
Property Plant and Equipment Gross 17,788
Short Long Term Debt Total 10,457



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-31
> Total Assets 
22,228
0
0
0
42,824
34,723
91,317
85,779
89,301
73,856
117,025
109,723
101,100
89,937
73,437
60,323
44,482
62,482
46,947
39,544
99,569
88,800
75,206
180,996
165,435
176,746
180,522
167,162
159,883
145,696
188,068
178,265
165,886
155,693
139,506
106,034
305,050
325,207
325,207305,050106,034139,506155,693165,886178,265188,068145,696159,883167,162180,522176,746165,435180,99675,20688,80099,56939,54446,94762,48244,48260,32373,43789,937101,100109,723117,02573,85689,30185,77991,31734,72342,82400022,228
   > Total Current Assets 
19,112
0
0
0
38,913
29,886
89,047
83,397
86,816
71,486
114,578
107,352
98,680
84,984
68,835
55,568
42,076
59,528
44,449
36,119
96,667
74,440
61,052
166,502
151,343
163,125
166,812
151,768
144,443
130,007
172,572
159,677
148,138
138,392
122,725
89,869
90,729
111,109
111,10990,72989,869122,725138,392148,138159,677172,572130,007144,443151,768166,812163,125151,343166,50261,05274,44096,66736,11944,44959,52842,07655,56868,83584,98498,680107,352114,57871,48686,81683,39789,04729,88638,91300019,112
       Cash And Cash Equivalents 
16,592
0
0
0
32,337
17,051
82,648
59,488
58,656
26,637
82,630
72,151
70,622
58,304
60,237
50,485
37,403
32,173
30,200
34,234
89,893
72,606
59,730
146,261
138,685
125,407
125,749
114,645
114,057
113,437
138,057
112,843
106,727
125,925
112,027
79,603
76,911
103,418
103,41876,91179,603112,027125,925106,727112,843138,057113,437114,057114,645125,749125,407138,685146,26159,73072,60689,89334,23430,20032,17337,40350,48560,23758,30470,62272,15182,63026,63758,65659,48882,64817,05132,33700016,592
       Short-term Investments 
1,244
0
0
0
4,125
8,928
1,900
19,788
25,485
41,885
30,025
32,237
25,940
24,839
5,991
0
0
16,244
11,480
0
0
0
0
0
0
22,405
24,389
24,018
13,998
3,997
3,999
33,599
28,164
0
0
0
0
0
0000028,16433,5993,9993,99713,99824,01824,38922,40500000011,48016,244005,99124,83925,94032,23730,02541,88525,48519,7881,9008,9284,1250001,244
       Net Receivables 
674
0
0
0
824
1,627
1,961
483
215
63
1
0
63
52
0
0
0
0
0
0
5,000
5,000
0
12,626
7,224
8,342
8,464
7,324
9,914
7,153
24,294
7,025
9,858
8,682
6,440
6,773
8,851
4,376
4,3768,8516,7736,4408,6829,8587,02524,2947,1539,9147,3248,4648,3427,22412,62605,0005,000000000526301632154831,9611,627824000674
       Other Current Assets 
602
0
0
0
1,627
2,280
2,538
3,638
2,460
2,901
1,922
2,964
2,055
1,789
2,607
5,083
4,673
11,111
2,769
1,885
1,774
1,834
1,322
7,615
5,434
6,971
8,210
5,781
6,474
5,420
6,222
6,210
3,389
3,785
4,258
3,493
4,967
3,315
3,3154,9673,4934,2583,7853,3896,2106,2225,4206,4745,7818,2106,9715,4347,6151,3221,8341,7741,8852,76911,1114,6735,0832,6071,7892,0552,9641,9222,9012,4603,6382,5382,2801,627000602
   > Long-term Assets 
0
0
0
0
3,911
4,837
2,270
2,382
2,485
2,370
2,447
2,371
2,420
4,953
4,602
4,755
2,406
2,954
2,498
3,425
2,902
14,360
14,154
14,494
14,092
13,621
13,710
15,394
15,440
15,689
15,496
18,588
17,748
17,301
16,781
16,165
214,321
214,098
214,098214,32116,16516,78117,30117,74818,58815,49615,68915,44015,39413,71013,62114,09214,49414,15414,3602,9023,4252,4982,9542,4064,7554,6024,9532,4202,3712,4472,3702,4852,3822,2704,8373,9110000
       Property Plant Equipment 
1,983
0
0
0
2,029
2,040
1,954
2,066
2,047
2,054
2,131
2,055
2,091
2,257
2,137
2,109
2,127
2,954
2,498
2,046
1,523
12,981
12,775
12,579
12,343
11,977
12,177
11,924
11,971
12,225
12,071
14,960
14,411
13,966
13,368
12,760
12,181
11,958
11,95812,18112,76013,36813,96614,41114,96012,07112,22511,97111,92412,17711,97712,34312,57912,77512,9811,5232,0462,4982,9542,1272,1092,1372,2572,0912,0552,1312,0542,0472,0661,9542,0402,0290001,983
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48,163
48,163
48,16348,163000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,000
2,000
2,000
2,000
2,000
2,000
2,000
2,000
2,000
2,000
2,000
2,0002,0002,0002,0002,0002,0002,0002,0002,0002,0002,000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
150,600
150,600
150,600150,600000000000000000000000000000000000000
       Long-term Assets Other 
0
0
0
0
1,882
2,797
316
316
438
316
316
316
329
2,696
2,465
2,646
279
279
2,498
1,379
1,379
1,379
1,379
1,915
1,749
1,644
1,533
1,470
1,469
1,464
46
28
0
1,335
1,413
1,405
1,377
1,377
1,3771,3771,4051,4131,335028461,4641,4691,4701,5331,6441,7491,9151,3791,3791,3791,3792,4982792792,6462,4652,6963293163163164383163162,7971,8820000
> Total Liabilities 
15,950
0
0
0
159,317
20,381
22,541
20,336
34,344
32,766
38,843
44,647
49,286
48,355
49,175
50,323
49,900
47,663
46,891
44,459
91,172
97,563
88,258
188,378
183,441
196,317
184,744
185,893
137,362
89,932
98,462
93,358
72,058
81,114
74,058
45,705
745,234
442,007
442,007745,23445,70574,05881,11472,05893,35898,46289,932137,362185,893184,744196,317183,441188,37888,25897,56391,17244,45946,89147,66349,90050,32349,17548,35549,28644,64738,84332,76634,34420,33622,54120,381159,31700015,950
   > Total Current Liabilities 
9,231
0
0
0
7,290
6,317
8,939
7,690
13,706
13,304
20,053
11,322
10,973
11,810
13,891
34,632
35,144
33,046
31,908
29,478
34,943
30,072
22,510
77,004
81,547
84,607
87,296
95,616
72,251
39,246
33,763
23,728
25,077
26,531
29,367
19,939
68,209
36,654
36,65468,20919,93929,36726,53125,07723,72833,76339,24672,25195,61687,29684,60781,54777,00422,51030,07234,94329,47831,90833,04635,14434,63213,89111,81010,97311,32220,05313,30413,7067,6908,9396,3177,2900009,231
       Short-term Debt 
2,578
0
0
0
3,378
673
1,781
2,913
4,067
4,519
4,612
20,954
21,042
21,127
21,212
21,299
21,385
22,894
22,633
21,661
19,277
18,293
10,032
875
908
1,402
3,268
5,138
7,010
1,783
4,410
7,431
10,084
11,889
11,964
1,787
2,166
2,229
2,2292,1661,78711,96411,88910,0847,4314,4101,7837,0105,1383,2681,40290887510,03218,29319,27721,66122,63322,89421,38521,29921,21221,12721,04220,9544,6124,5194,0672,9131,7816733,3780002,578
       Short Long Term Debt 
2,578
0
0
0
11,855
0
0
0
4,067
4,519
10,344
20,954
21,042
21,127
21,212
21,299
21,385
21,466
21,548
20,927
18,905
16,868
8,384
0
0
460
2,291
4,125
5,961
696
3,285
5,879
8,476
10,218
10,235
0
0
0
00010,23510,2188,4765,8793,2856965,9614,1252,291460008,38416,86818,90520,92721,54821,46621,38521,29921,21221,12721,04220,95410,3444,5194,06700011,8550002,578
       Accounts payable 
351
0
0
0
2,179
788
943
1,040
3,882
1,317
4,280
1,519
1,606
1,789
1,789
1,252
1,100
693
2,463
1,478
500
1,330
1,242
471
443
594
154
1,593
224
264
693
214
316
1,063
267
375
3,150
2,517
2,5173,1503752671,0633162146932642241,5931545944434711,2421,3305001,4782,4636931,1001,2521,7891,7891,6061,5194,2801,3173,8821,0409437882,179000351
       Other Current Liabilities 
6,302
0
0
0
420
3,637
4,973
2,696
3,921
5,521
8,595
6,547
8,580
9,062
10,184
10,218
11,700
8,500
5,789
5,316
13,492
8,775
9,308
11,285
8,146
6,847
8,861
26,570
11,134
9,209
12,686
12,263
14,084
9,347
12,902
13,637
60,582
31,496
31,49660,58213,63712,9029,34714,08412,26312,6869,20911,13426,5708,8616,8478,14611,2859,3088,77513,4925,3165,7898,50011,70010,21810,1849,0628,5806,5478,5955,5213,9212,6964,9733,6374200006,302
   > Long-term Liabilities 
0
0
0
0
152,027
14,064
13,602
12,646
20,638
19,462
18,790
33,325
38,313
36,545
35,284
15,691
14,756
14,617
14,983
14,981
56,229
67,491
65,748
111,374
101,894
111,710
97,448
90,277
65,111
50,686
64,699
69,630
46,981
54,583
44,691
25,766
677,025
405,353
405,353677,02525,76644,69154,58346,98169,63064,69950,68665,11190,27797,448111,710101,894111,37465,74867,49156,22914,98114,98314,61714,75615,69135,28436,54538,31333,32518,79019,46220,63812,64613,60214,064152,0270000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24,589
24,793
24,551
22,931
21,304
19,673
25,042
22,634
20,215
17,786
16,228
13,787
0
0
0
00013,78716,22817,78620,21522,63425,04219,67321,30422,93124,55124,79324,58900000000000000000000000
       Capital Lease Obligations Min Short Term Debt
-2,578
0
0
0
-3,378
-673
-1,781
-2,913
-4,067
-4,519
-4,612
-20,954
-21,042
-21,127
-21,212
-21,299
-21,385
-21,466
-21,548
-20,927
-18,905
-6,428
1,736
9,886
9,647
8,943
6,852
4,748
2,637
7,620
4,733
4,627
1,579
-601
-1,072
8,694
8,789
8,228
8,2288,7898,694-1,072-6011,5794,6274,7337,6202,6374,7486,8528,9439,6479,8861,736-6,428-18,905-20,927-21,548-21,466-21,385-21,299-21,212-21,127-21,042-20,954-4,612-4,519-4,067-2,913-1,781-673-3,378000-2,578
       Warrants
0
0
0
0
0
0
5,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000005,000000000
       Other Liabilities 
1,895
0
0
0
2,690
3,205
3,474
3,582
12,661
12,595
13,058
12,371
17,271
15,418
14,072
15,691
14,756
14,617
14,983
14,981
56,229
57,051
49,179
76,899
67,454
77,756
65,374
60,100
36,840
17,328
34,047
38,909
0
0
0
0
0
0
00000038,90934,04717,32836,84060,10065,37477,75667,45476,89949,17957,05156,22914,98114,98314,61714,75615,69114,07215,41817,27112,37113,05812,59512,6613,5823,4743,2052,6900001,895
> Total Stockholder Equity
6,278
0
0
0
-116,493
14,342
68,776
65,443
54,957
41,090
78,182
65,076
51,814
41,582
24,262
10,000
-5,418
14,819
56
-4,915
8,397
-8,763
-13,052
-7,382
-18,006
-19,571
-4,222
-18,731
22,521
55,764
89,606
84,907
93,828
74,579
65,448
60,329
-440,184
-116,800
-116,800-440,18460,32965,44874,57993,82884,90789,60655,76422,521-18,731-4,222-19,571-18,006-7,382-13,052-8,7638,397-4,9155614,819-5,41810,00024,26241,58251,81465,07678,18241,09054,95765,44368,77614,342-116,4930006,278
   Common Stock
1
0
0
0
1
1
1
1
1
1
1
2
3
3
3
3
3
5
5
5
9
9
10
11
11
11
12
12
12
12
15
15
15
15
15
15
16
1
11615151515151512121212111111109955533333211111110001
   Retained Earnings Total Equity0000-416,600-394,937-400,830-392,937-401,538-430,316-442,555-424,661-429,226-404,629-389,1830000000000000000-129,765000000
   Accumulated Other Comprehensive Income -4,605-4,600-4,616-4,596-4,569-4,558-4,530-4,480-4,598-4,566-4,559-4,557-4,570-4,563-4,584-4,552-4,583-4,523-4,533-4,525-4,533-4,557-4,517-4,476-4,398-4,420-4,409-4,413-4,380-4,518-4,554-4,585-4,755-4,9860000
   Capital Surplus 
0
0
0
0
0
0
203,125
0
0
0
0
0
0
0
0
0
279,539
311,824
313,447
320,478
348,664
351,184
0
386,374
391,175
414,214
424,984
428,371
457,391
461,888
487,008
490,252
493,308
495,733
498,016
0
0
0
000498,016495,733493,308490,252487,008461,888457,391428,371424,984414,214391,175386,3740351,184348,664320,478313,447311,824279,539000000000203,125000000
   Treasury Stock00000000000000000000000000000000000000
   Other Stockholders Equity 
-3,876
0
0
0
1
138,521
201,857
207,935
211,532
138,323
264,858
266,427
272,708
273,936
275,412
278,151
279,982
312,291
313,922
320,945
349,141
351,601
371,392
386,790
391,175
414,214
424,984
428,371
457,391
461,888
487,008
490,252
493,308
495,733
498,016
501,919
-117,804
559,275
559,275-117,804501,919498,016495,733493,308490,252487,008461,888457,391428,371424,984414,214391,175386,790371,392351,601349,141320,945313,922312,291279,982278,151275,412273,936272,708266,427264,858138,323211,532207,935201,857138,5211000-3,876



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue26,004
Cost of Revenue-1,553
Gross Profit24,45124,451
 
Operating Income (+$)
Gross Profit24,451
Operating Expense-112,420
Operating Income-86,416-87,969
 
Operating Expense (+$)
Research Development71,839
Selling General Administrative40,581
Selling And Marketing Expenses0
Operating Expense112,420112,420
 
Net Interest Income (+$)
Interest Income0
Interest Expense-2,833
Other Finance Cost-0
Net Interest Income-2,833
 
Pretax Income (+$)
Operating Income-86,416
Net Interest Income-2,833
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-238,71063,045
EBIT - interestExpense = -88,558
-238,710
-216,877
Interest Expense2,833
Earnings Before Interest and Taxes (EBIT)-85,725-235,877
Earnings Before Interest and Taxes (EBITDA)-84,882
 
After tax Income (+$)
Income Before Tax-238,710
Tax Provision--19,000
Net Income From Continuing Ops-219,710-219,710
Net Income-219,710
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses112,420
Total Other Income/Expenses Net-149,4612,833
 

Technical Analysis of Cartesian Therapeutics Inc.
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cartesian Therapeutics Inc.. The general trend of Cartesian Therapeutics Inc. is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cartesian Therapeutics Inc.'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cartesian Therapeutics Inc..

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 20.50 < 21.24 < 41.87.

The bearish price targets are: 11.67.

Tweet this
Cartesian Therapeutics Inc. Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cartesian Therapeutics Inc.. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cartesian Therapeutics Inc. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cartesian Therapeutics Inc.. The current macd is -1.8513103.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cartesian Therapeutics Inc. price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cartesian Therapeutics Inc.. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cartesian Therapeutics Inc. price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Cartesian Therapeutics Inc. Daily Moving Average Convergence/Divergence (MACD) ChartCartesian Therapeutics Inc. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cartesian Therapeutics Inc.. The current adx is 23.81.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Cartesian Therapeutics Inc. shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Cartesian Therapeutics Inc. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cartesian Therapeutics Inc.. The current sar is 29.37.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Cartesian Therapeutics Inc. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cartesian Therapeutics Inc.. The current rsi is 35.70. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Cartesian Therapeutics Inc. Daily Relative Strength Index (RSI) ChartCartesian Therapeutics Inc. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cartesian Therapeutics Inc.. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cartesian Therapeutics Inc. price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Cartesian Therapeutics Inc. Daily Stochastic Oscillator ChartCartesian Therapeutics Inc. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cartesian Therapeutics Inc.. The current cci is -144.93983868.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Cartesian Therapeutics Inc. Daily Commodity Channel Index (CCI) ChartCartesian Therapeutics Inc. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cartesian Therapeutics Inc.. The current cmo is -35.74186363.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Cartesian Therapeutics Inc. Daily Chande Momentum Oscillator (CMO) ChartCartesian Therapeutics Inc. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cartesian Therapeutics Inc.. The current willr is -86.18638467.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Cartesian Therapeutics Inc. Daily Williams %R ChartCartesian Therapeutics Inc. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cartesian Therapeutics Inc..

Cartesian Therapeutics Inc. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cartesian Therapeutics Inc.. The current atr is 3.68642819.

Cartesian Therapeutics Inc. Daily Average True Range (ATR) ChartCartesian Therapeutics Inc. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cartesian Therapeutics Inc.. The current obv is -763,460.

Cartesian Therapeutics Inc. Daily On-Balance Volume (OBV) ChartCartesian Therapeutics Inc. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cartesian Therapeutics Inc.. The current mfi is 28.43.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Cartesian Therapeutics Inc. Daily Money Flow Index (MFI) ChartCartesian Therapeutics Inc. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cartesian Therapeutics Inc..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-10MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-26MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-05-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-05-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-05-31ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-06-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-04MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-06-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-06-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Cartesian Therapeutics Inc. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cartesian Therapeutics Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5035.703
Ma 20Greater thanMa 5026.650
Ma 50Greater thanMa 10025.899
Ma 100Greater thanMa 20022.597
OpenGreater thanClose16.160
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cartesian Therapeutics Inc. with someone you think should read this too:
  • Are you bullish or bearish on Cartesian Therapeutics Inc.? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cartesian Therapeutics Inc.? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cartesian Therapeutics Inc.

I send you an email if I find something interesting about Cartesian Therapeutics Inc..


Stay informed about Cartesian Therapeutics Inc..

Receive notifications about Cartesian Therapeutics Inc. in your mailbox!